Research perspective: potential role of nitazoxanide in ovarian cancer treatment. Old drug, new purpose? - PubMed (original) (raw)
Research perspective: potential role of nitazoxanide in ovarian cancer treatment. Old drug, new purpose?
Nicola Di Santo et al. Cancers (Basel). 2013.
Abstract
Among gynecological malignancies epithelial ovarian cancer (EOC) is the leading cause of death. Despite improvements in conventional chemotherapy combinations, the overall cure rate has remained mostly stable over the years, and only 10%-15% of patients maintain a complete response following first-line therapy. To improve the efficacy of ovarian cancer chemotherapy it is essential to develop drugs with new mechanisms of action. Compared to normal tissues, protein disulfide isomerase (PDI) is overexpressed in ovarian tumors. PDI is a cellular enzyme in the lumen of the endoplasmic reticulum (ER) of eukaryotes or the periplasmic region of prokaryotes. This protein catalyzes the formation and breakage of disulphide bonds between cysteine residues in proteins, which affects protein folding. Selective inhibition of PDI activity has been exhibited both in vitro and in vivo anticancer activity in human ovarian cancer models. PDI inhibition caused accumulation of unfolded or misfolded proteins, which led to ER stress and the unfolded protein response (UPR), and in turn resulted in cell death. Nitazoxanide [NTZ: 2-acetyloxy-N-(5-nitro-2-thiazolyl)benzamide] is a thiazolide antiparasitic agent with excellent activity against a wide variety of protozoa and helminths. In this article, we propose that NTZ, acting as PDI inhibitor, may be a new and potent addition to the chemotherapeutic strategy against ovarian cancer.
Figures
Figure 1
Schematic of autophagy mechanism.
Figure 2
Chemical structure of nitozoxanide.
Similar articles
- Nitrosative stress-induced s-glutathionylation of protein disulfide isomerase leads to activation of the unfolded protein response.
Townsend DM, Manevich Y, He L, Xiong Y, Bowers RR Jr, Hutchens S, Tew KD. Townsend DM, et al. Cancer Res. 2009 Oct 1;69(19):7626-34. doi: 10.1158/0008-5472.CAN-09-0493. Epub 2009 Sep 22. Cancer Res. 2009. PMID: 19773442 Free PMC article. - Protein disulphide isomerase inhibition as a potential cancer therapeutic strategy.
Powell LE, Foster PA. Powell LE, et al. Cancer Med. 2021 Apr;10(8):2812-2825. doi: 10.1002/cam4.3836. Epub 2021 Mar 20. Cancer Med. 2021. PMID: 33742523 Free PMC article. Review. - A functional perspective of nitazoxanide as a potential anticancer drug.
Di Santo N, Ehrisman J. Di Santo N, et al. Mutat Res. 2014 Oct;768:16-21. doi: 10.1016/j.mrfmmm.2014.05.005. Epub 2014 Jun 2. Mutat Res. 2014. PMID: 25847384 Review. - S-nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration.
Uehara T, Nakamura T, Yao D, Shi ZQ, Gu Z, Ma Y, Masliah E, Nomura Y, Lipton SA. Uehara T, et al. Nature. 2006 May 25;441(7092):513-7. doi: 10.1038/nature04782. Nature. 2006. PMID: 16724068 - Discovery of an orally active small-molecule irreversible inhibitor of protein disulfide isomerase for ovarian cancer treatment.
Xu S, Butkevich AN, Yamada R, Zhou Y, Debnath B, Duncan R, Zandi E, Petasis NA, Neamati N. Xu S, et al. Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):16348-53. doi: 10.1073/pnas.1205226109. Epub 2012 Sep 17. Proc Natl Acad Sci U S A. 2012. PMID: 22988091 Free PMC article.
Cited by
- Neurocysticercosis: a review on status in India, management, and current therapeutic interventions.
Ahmad R, Khan T, Ahmad B, Misra A, Balapure AK. Ahmad R, et al. Parasitol Res. 2017 Jan;116(1):21-33. doi: 10.1007/s00436-016-5278-9. Epub 2016 Oct 24. Parasitol Res. 2017. PMID: 27774576 Review. - Electrochemical DNA biosensors developed for the monitoring of biointeractions with drugs: a review.
Erdem A, Şentürk H, Yildiz E, Maral M, Yildirim A, Bozoğlu A, Kivrak B, Ay NC. Erdem A, et al. Turk J Chem. 2023 Sep 30;47(5):864-887. doi: 10.55730/1300-0527.3584. eCollection 2023. Turk J Chem. 2023. PMID: 38173734 Free PMC article. - Nitazoxanide inhibits acetylated KLF5-induced bone metastasis by modulating KLF5 function in prostate cancer.
Huang Q, Liu M, Zhang D, Lin BB, Fu X, Zhang Z, Zhang B, Dong JT. Huang Q, et al. BMC Med. 2023 Feb 21;21(1):68. doi: 10.1186/s12916-023-02763-4. BMC Med. 2023. PMID: 36810084 Free PMC article. - NSAIDs/nitazoxanide/azithromycin repurposed for COVID-19: potential mitigation of the cytokine storm interleukin-6 amplifier via immunomodulatory effects.
Kelleni MT. Kelleni MT. Expert Rev Anti Infect Ther. 2022 Jan;20(1):17-21. doi: 10.1080/14787210.2021.1939683. Epub 2021 Jun 15. Expert Rev Anti Infect Ther. 2022. PMID: 34088250 Free PMC article. - Ultrastructural changes and IgA modulatory effect of commercial prebiotic and probiotic in murine giardiasis.
Hassan ZR, Salama DEA, Ibrahim HF, Ahmed SG. Hassan ZR, et al. J Parasit Dis. 2023 Jun;47(2):224-237. doi: 10.1007/s12639-022-01552-9. Epub 2022 Dec 20. J Parasit Dis. 2023. PMID: 37193505 Free PMC article.
References
- Xu S., Butkevich A.N., Yamada R., Zhou Y., Debnath B., Duncan R., Zandi E., Petasis N.A., Neamati N. Discovery of an orally active small-molecule irreversible inhibitor of protein disulfide isomerase for ovarian cancer treatment. Proc. Natl. Acad. Sci. USA. 2012;109:16348–16353. doi: 10.1073/pnas.1205226109. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources